Baker 1031Investor Workspace
Welcome, there!Log Out

Available Investments

Explore opportunities and save the ones you’d like to discuss.

Investment inventoryAvailability is subject to confirmation.

Includes available, under review, and limited availability.

Try , , or a sponsor’s name.

Loading investments…

Sort by

A good investment starts with the right questions. Let’s talk through yours

© 2026 Baker 1031 InvestmentsAvailability subject to confirmation
Baker 1031

Investor workspace · Airtable inventory

Find your fit.

Choose one or more options in each category.

Property & sponsor
Property type
Investment sponsor
Location
Availability
Investment preferences
721 exit
Exchange LTV
Investment details /
Property image

The investment at a glance.

THE NUMBERS

Financials

Investment terms and annual figures from the investment record.

Annual cash flow

Year-by-year cash flow from the investment record.

Figures are not guaranteed. The average is the arithmetic mean of populated year fields, not IRR or total return. Review the offering documents for assumptions and details.

THE DETAILS BEHIND THE DECISION

Documents

Review the source materials for this investment.

Folder contents are maintained by Baker 1031. Documents open in their original shared folder.

Availability and terms are subject to confirmation.

Discuss with Jerry

NexPoint Life Sciences III DST

NexPoint Life Sciences III DST owns a 137,811-square-foot medical-device research and development facility in Woodbury, Minnesota. Built in 2021, the property is leased to Kindeva Drug Delivery, a contract development and manufacturing organization specializing in drug-device combination products. The initial lease extends through September 2036 and includes three five-year renewal options.

Overview and financials

Sponsor
NexPoint
Status
Available
Property type
Life Sciences, NNN
Location
Minnesota
Estimated hold
5 Years
Minimum investment
$100,000
Exchange LTV
50.52%
721 exit
Optional
Average of provided years
4.07%

Annual cash flow

Source figures supplied by the investment sponsor
YearCash flow
14.18%
24.03%
34.01%
44.04%
54.06%
64.06%
74.07%
84.07%
94.10%
10Not provided

Documents

Open due-diligence folder

Availability is subject to confirmation. Investments involve risk, including possible loss of principal and illiquidity. Source figures are not guarantees of future performance.

Opening your workspace…